Markets
EC

Novo Nordisk's Saxenda Gets EU Approval for Obesity - Analyst Blog

A generic image of a pen next to a pile of coins
Credit: Shutterstock photo

Novo Nordisk A/SNVO announced that Saxenda (liraglutide 3mg) received marketing authorization from the European Commission (EC), for the treatment of obesity.

Given that the Committee for Medicinal Products for Human Use adopted a positive opinion on the use of Saxenda for the treatment of obesity in Jan 2015, the EC's decision was expected.

The authorization will cover all the 28 member states in the EU. Currently, Saxenda is the first once-daily human glucagon-like peptide-1 (GLP-1) analogue approved in Europe as an adjunct to a reduced-calorie diet and increased physical activity for weight management in patients having an initial Body Mass Index (BMI) of ≥30 kg/m2 (obese) or ≥27 kg/m2 to

Novo Nordisk intends to launch Saxenda in several European countries starting 2015.

We note that Saxenda is already approved in the U.S. and Canada as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients suffering from obesity (BMI ≥30 kg/m2) or overweight patients (BMI ≥27 kg/m2) with at least one weight-related comorbidity.

Our Take

We are encouraged by the approval of Saxenda in the EU. We believe that the increasing prevalence of obesity across the world and its association with modern-day lifestyle provides ample opportunity for new drugs like Saxenda. According to Novo Nordisk, approximately 10% - 30% of the adult population in the EU suffers from the disease.

Moreover, given the U.S. and EU patent expiry of two drugs in Novo Nordisk's portfolio (NovoRapid/NovoLog and NovoLog Mix/NovoMix) in 2014 and the upcoming patent expiry on Norditropin (both the U.S. and the EU in 2017), Saxenda's European approval is an important event for the company.

Novo Nordisk carries a Zacks Rank #2 (Buy). Other well-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP , Cytokinetics, Incorporated CYTK and Horizon Pharma plc HZNP . All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

HORIZON PHARMA (HZNP): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

EC HZNP CYTK BMI NVO

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More